

# **MEDICAL LABORATORY EVALUATION**

## **PARTICIPANT SUMMARY**

**2 • 0 • 0 • 7**

**Please see the corresponding US participant summary for any statistics not represented in this supplement.**



Total Commitment to Education and Service  
Provided by ACP Services, Inc.

**International Data Supplement  
MLE – M1**

# Table of Contents

<b>2007 Evaluation Criteria</b> .....	<b>3</b>
<b>Coagulation</b>	
<b>Prothrombin Time</b> .....	4
International Normalized Ratio (INR) .....	5
<b>Activated Partial Thromboplastin Time</b> .....	7
<b>Fibrinogen</b> .....	8
<b>Urinalysis</b>	
<b>Urinalysis Dipstick</b> .....	9
Specific Gravity .....	9
pH .....	9
Protein .....	10
Glucose or Reducing Substance .....	10
Ketones.....	11
Bilirubin .....	11
Urobilinogen.....	12
Blood or Hemoglobin .....	12
Leukocyte Esterase .....	13
Nitrite .....	13
Microalbumin (Dipstick Only) .....	14
<b>Urine hcG</b> .....	14
<b>Microbiology</b>	
<b>Antimicrobial Susceptibility Testing</b> .....	15
<b>Parasitology (PA Specimens)</b> .....	16
<b>Parasitology (FP Specimens)</b> .....	17
<b>Immunology</b>	
<b>Syphilis Serology</b> .....	18
VDRL Slide .....	18
VDRL Slide (Titer).....	19
MHA-TP .....	19
FTA-ABS.....	19
RPR .....	20
RPR (Titer).....	20
<b>Viral Markers</b> .....	21
Anti-HBc.....	21
Anti-HIV .....	22
HAV .....	23
HBeAg .....	24
HBsAb.....	25
HBsAg.....	26
HCV .....	27
<b>Chemistry</b>	
<b>Blood Gases</b> .....	28

## 2007 Evaluation Criteria

The evaluation criteria used in the 2007 MLE Program is in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) federal requirements for proficiency testing. The criteria are included below.

### Qualitative

For qualitative procedures, evaluation is based on participant consensus. A minimum percentage of participants must receive a passing score or the challenge is not evaluated due to lack of consensus. These percentages are listed below.

Antimicrobial Susceptibility Testing	80% Consensus
Microalbumin (Semi-Quantitative)	80% Consensus
Parasite Identification	80% Consensus
Syphilis Serology	80% Consensus
Urine Dipstick	80% Consensus
Urine hCG	80% Consensus
Viral Markers	80% Consensus

### Quantitative

For quantitative procedures, a mean and standard deviation (SD) are calculated for each peer group consisting of 5 or more laboratories. Acceptable performance is established based on a target value  $\pm$  the intervals below. An explanation on how to calculate the range of acceptability based upon these limits is also provided in your MLE Program Guide on pages 39-40 under the heading "Acceptable Ranges for Quantitative Results."

Activated Partial Thromboplastin Time	$\pm$ 15 percent
Calcium, Ionized	$\pm$ 3 SD
Chloride	$\pm$ 5%
Fibrinogen	$\pm$ 20 percent
International Normalized Ratio	$\pm$ 3 SD
pCO <sub>2</sub>	$\pm$ 5 mmHg or 8% *
pH	$\pm$ 0.04
pO <sub>2</sub>	$\pm$ 3 SD
Potassium	$\pm$ 0.5 mmol/L
Prothrombin Time	$\pm$ 15 percent
Sodium	$\pm$ 4.0 mmol/L
Specific Gravity	$\pm$ 0.010



**PROTHROMBIN TIME (seconds)**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Specimen CG-5</u>			<u>Median</u>
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	
All Method	110	31.51	6.22	19.7	31.5
bioMerieux Simplastin Excel S					
bioMerieux Thrombotimer	4	-	-	-	39.6
All Coagulation Instruments	10	38.96	3.11	8.0	39.9
Dade Innovin					
Sysmex CA-1000/1500	5	26.24	1.27	4.8	26.3
All Coagulation Instruments	10	25.36	1.47	5.8	25.2
Dade Thromborel S					
Other Instrument Specified	5	35.72	5.62	15.7	38.2
Sysmex CA-500	9	36.97	2.87	7.8	36.6
All Coagulation Instruments	22	36.71	3.97	10.8	38.2
Diag Stago STA Neoplastine CI+					
RAL Clot-SP	10	36.87	0.90	2.5	37.0
All Coagulation Instruments	11	36.62	1.20	3.3	36.9
IL TEST PT-FIB HS PLUS					
All Coagulation Instruments	3	-	-	-	33.9
IL TEST PT-FIB HS					
IL ACL, all models	12	26.35	2.85	10.8	26.1
IL TEST PT-FIB Recombinant					
IL ACL, all models	23	28.10	2.61	9.3	28.0
All Coagulation Instruments	24	27.98	2.62	9.4	28.0

**PROTHROMBIN TIME-INTERNATIONAL NORMALIZED RATIO (INR)**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Specimen CG-1</u>				<u>Specimen CG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	109	4.80	0.99	20.6	4.8	112	1.03	0.08	8.2	1.0
bioMerieux Simplastin Excel S										
bioMerieux Thrombotimer	5	5.20	0.48	9.3	5.1	5	1.08	0.04	4.1	1.1
All Coagulation Instruments	12	5.12	0.52	10.1	5.1	12	1.10	0.06	5.5	1.1
Dade Innovin										
Sysmex CA-1000/1500	5	4.00	0.41	10.3	4.0	5	1.02	0.08	8.2	1.0
All Coagulation Instruments	10	3.90	0.48	12.3	4.0	10	0.99	0.07	7.5	1.0
Dade Thromborel S										
Other Instrument Specified	5	5.06	0.36	7.2	4.9	5	1.04	0.09	8.6	1.1
Sysmex CA-500	8	4.94	0.85	17.3	5.2	8	0.99	0.04	3.6	1.0
All Coagulation Instruments	21	5.02	0.79	15.7	5.1	21	1.03	0.08	7.7	1.0
Diag Stago STA Neoplastine CI+										
RAL Clot-SP	10	6.23	0.27	4.3	6.1	10	1.08	0.04	3.9	1.1
All Coagulation Instruments	11	6.05	0.66	11.0	6.1	11	1.07	0.05	4.4	1.1
IL TEST PT-FIB HS PLUS										
All Coagulation Instruments	5	4.68	2.22	47.4	5.1	5	0.98	0.04	4.6	1.0
IL TEST PT-FIB HS										
IL ACL, all models	12	5.68	1.57	27.5	5.6	12	1.04	0.14	13.9	1.0
IL TEST PT-FIB Recombinant										
IL ACL, all models	22	4.22	0.62	14.7	4.2	22	1.00	0.08	8.4	1.0
All Coagulation Instruments	23	4.21	0.61	14.4	4.2	23	1.01	0.08	8.4	1.0





**ACTIVATED PARTIAL THROMBOPLASTIN (seconds)**

**Specimen CG-5**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	97	55.7	9.9	17.8	54
bioMerieux autoAPTT Reagent					
bioMerieux Thrombotimer	5	54.8	7.7	14.0	54
All Coagulation Instruments	9	56.1	6.0	10.7	57
Dade Actin FS					
Sysmex CA-1000/1500	4	-	-	-	77
Sysmex CA-500	5	68.6	9.8	14.3	72
All Coagulation Instruments	10	68.5	9.6	14.0	72
Dade Actin FSL					
Sysmex CA-500	6	54.3	5.5	10.1	54
All Coagulation Instruments	12	55.3	4.7	8.5	54
Dade Actin					
All Coagulation Instruments	6	70.5	6.3	8.9	72
IL TEST APTT-SP					
IL ACL, all models	30	49.4	3.3	6.7	49
All Coagulation Instruments	33	49.2	4.2	8.4	49
Sysmex HemoStat aPTT - EL					
All Coagulation Instruments	9	50.8	7.9	15.5	52

**FIBRINOGEN (mg/dL)**

**Specimen CG-1**

**Specimen CG-2**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	62	294.5	66.5	22.6	290	62	202.4	48.2	23.8	185
Dade Fibrinogen Set										
Sysmex CA-500	7	250.6	41.9	16.7	262	6	232.8	36.7	15.8	245
All Coagulation Instruments	15	253.8	38.4	15.1	262	13	242.2	29.1	12.0	254
IL TEST PT Fibrinogen										
IL ACL, all models	5	347.4	27.0	7.8	362	6	199.3	34.2	17.2	199
IL TEST PT-FIB HS										
IL ACL, all models	10	376.0	29.5	7.9	369	10	161.2	20.2	12.5	163
IL TEST PT-FIB Recombinant										
IL ACL, all models	12	296.0	34.5	11.7	298	13	174.8	12.6	7.2	177
Sysmex HemoStat Fibrinogen										
All Coagulation Instruments	5	215.2	62.9	29.2	223	5	261.6	62.9	24.1	270

**Specimen CG-3**

**Specimen CG-4**

All Method	61	178.8	27.9	15.6	175	60	406.4	61.9	15.2	405
Dade Fibrinogen Set										
Sysmex CA-500	6	171.2	13.6	7.9	172	6	403.8	40.7	10.1	405
All Coagulation Instruments	14	173.6	36.0	20.7	164	12	384.8	59.9	15.6	396
IL TEST PT Fibrinogen										
IL ACL, all models	6	222.2	31.0	13.9	242	4	-	-	-	435
IL TEST PT-FIB HS										
IL ACL, all models	10	164.5	20.3	12.3	168	10	432.8	28.6	6.6	435
IL TEST PT-FIB Recombinant										
IL ACL, all models	13	186.6	23.6	12.6	187	14	413.9	41.1	9.9	412
Sysmex HemoStat Fibrinogen										
All Coagulation Instruments	5	172.4	20.1	11.6	173	6	400.8	84.8	21.1	384

## FIBRINOGEN (mg/dL)

### Specimen CG-5

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	60	321.4	51.7	16.1	322
Dade Fibrinogen Set					
Sysmex CA-500	6	275.5	24.4	8.8	289
All Coagulation Instruments	13	279.6	28.7	10.3	272
IL TEST PT Fibrinogen					
IL ACL, all models	5	390.2	65.1	16.7	367
IL TEST PT-FIB HS					
IL ACL, all models	10	371.2	47.8	12.9	378
IL TEST PT-FIB Recombinant					
IL ACL, all models	14	334.1	44.6	13.3	325
Sysmex HemoStat Fibrinogen					
All Coagulation Instruments	5	289.6	39.2	13.5	281

## Urinalysis

### URINALYSIS DIPSTICK–SPECIFIC GRAVITY

#### Specimen UA-1

<u>Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	106	1.0120	0.0047	0.5	1.010
Arkray Aution Sticks	9	1.0239	0.0048	0.5	1.025
Bayer Clinitek 500	20	1.0113	0.0023	0.2	1.010
Bayer Reagent Strips	9	1.0100	0.0025	0.2	1.010
Roche (BMC) Chemstrips	25	1.0116	0.0041	0.4	1.010
Roche Urisys	5	1.0136	0.0061	0.6	1.015
UriScan Reagent Strips	13	1.0100	0.0020	0.2	1.010

### URINALYSIS DIPSTICK–pH

#### Specimen UA-1

#### Participant Results

<u>Method</u>	<u>3.5 or less</u>	<u>4.0</u>	<u>5.0</u>	<u>5.5</u>	<u>6.0</u>	<u>6.5</u>	<u>7.0</u>	<u>7.5</u>	<u>8.0</u>	<u>8.5</u>	<u>9.0</u>
ALL METHODS	-	-	-	-	1	-	3	24	82	-	1
Arkray Aution Sticks	-	-	-	-	-	-	-	7	2	-	-
Arkray PocketChem UA	-	-	-	-	-	-	-	-	2	-	-
Bayer Clinitek 10 / 100	-	-	-	-	-	-	-	-	1	-	-
Bayer Clinitek 50	-	-	-	-	-	-	-	-	2	-	-
Bayer Clinitek 500	-	-	-	-	-	-	-	2	19	-	-
Bayer Clinitek Atlas	-	-	-	-	-	-	-	2	1	-	-
Bayer Clinitek Status	-	-	-	-	-	-	-	-	1	-	-
Bayer Reagent Strips	-	-	-	-	-	-	-	-	9	-	-
BioScan Reagent Strips	-	-	-	-	-	-	-	-	1	-	-
Quidel QuickVue UrinChek	-	-	-	-	-	-	-	-	1	-	-
Roche (BMC) Chemstrips	-	-	-	-	1	-	1	-	21	-	1
Roche (BMC) Criterion Analyzer	-	-	-	-	-	-	-	-	2	-	-
Roche (BMC) Mini UA	-	-	-	-	-	-	1	-	3	-	-
Roche Miditron	-	-	-	-	-	-	-	-	2	-	-
Roche Urisys	-	-	-	-	-	-	-	-	5	-	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	-	-	-	-	4	-	-
UriScan Reagent Strips	-	-	-	-	-	-	-	12	1	-	-

**URINALYSIS DIPSTICK–PROTEIN QUALITATIVE**

**Specimen UA-1**

<u>Method</u>	<i>Participant Results</i>					
	<u>Negative</u>	<u>Trace</u>	<u>30mg/dL (1+)</u>	<u>100 mg/dL (2+)</u>	<u>300-500mg/dL (3+)</u>	<u>≥1000mg/dL (4+)</u>
ALL METHODS	107	2	1	-	1	-
Arkray Aution Sticks	9	-	-	-	-	-
Arkray PocketChem UA	2	-	-	-	-	-
Bayer Clinitek 10 / 100	1	-	-	-	-	-
Bayer Clinitek 50	2	-	-	-	-	-
Bayer Clinitek 500	21	-	-	-	-	-
Bayer Clinitek Atlas	3	-	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-	-
Bayer Reagent Strips	9	-	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-	-
Roche (BMC) Chemstrips	23	-	-	-	1	-
Roche (BMC) Criterion Analyzer	2	-	-	-	-	-
Roche (BMC) Mini UA	4	-	-	-	-	-
Roche Miditron	2	-	-	-	-	-
Roche Urisys	5	-	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-	-
UriScan Reagent Strips	10	2	1	-	-	-

**URINALYSIS DIPSTICK–GLUCOSE OR REDUCING SUBSTANCE**

**Specimen UA-1**

<u>Method</u>	<i>Participant Results</i>							
	<u>Negative</u>	<u>50-100 mg/dL (Trace)</u>	<u>150 mg/dL</u>	<u>250 mg/dL</u>	<u>500 mg/dL</u>	<u>1000 mg/dL</u>	<u>&gt;1000 mg/dL</u>	<u>≥2000 mg/dL</u>
ALL METHODS	110	1	-	-	-	-	-	-
Arkray Aution Sticks	9	-	-	-	-	-	-	-
Arkray PocketChem UA	2	-	-	-	-	-	-	-
Bayer Clinitek 10 / 100	1	-	-	-	-	-	-	-
Bayer Clinitek 50	2	-	-	-	-	-	-	-
Bayer Clinitek 500	21	-	-	-	-	-	-	-
Bayer Clinitek Atlas	3	-	-	-	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-	-	-	-
Bayer Reagent Strips	9	-	-	-	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-	-	-	-
Roche (BMC) Chemstrips	24	-	-	-	-	-	-	-
Roche (BMC) Criterion Analyzer	2	-	-	-	-	-	-	-
Roche (BMC) Mini UA	4	-	-	-	-	-	-	-
Roche Miditron	2	-	-	-	-	-	-	-
Roche Urisys	5	-	-	-	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-	-	-	-
UriScan Reagent Strips	12	1	-	-	-	-	-	-

## URINALYSIS DIPSTICK–KETONES

### Specimen UA-1

#### Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace (5 mg/dL)</u>	<u>Small (1+, 15 mg/dL)</u>	<u>Moderate (2+, 40 mg/dL)</u>	<u>Large (3+, 80 mg/dL)</u>
ALL METHODS	31	-	1	10	69
Arkray Aution Sticks	2	-	-	-	7
Arkray PocketChem UA	-	-	-	-	2
Bayer Clinitek 10 / 100	-	-	-	-	1
Bayer Clinitek 50	-	-	-	-	2
Bayer Clinitek 500	3	-	1	-	17
Bayer Clinitek Atlas	-	-	-	-	3
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	5	-	-	1	3
BioScan Reagent Strips	1	-	-	-	-
Quidel QuickVue UrinChek	-	-	-	-	1
Roche (BMC) Chemstrips	10	-	-	6	8
Roche (BMC) Criterion Analyzer	2	-	-	-	-
Roche (BMC) Mini UA	2	-	-	-	2
Roche Miditron	1	-	-	-	1
Roche Urisys	-	-	-	1	4
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Reagent Strips	1	-	-	-	12

## URINALYSIS DIPSTICK–BILIRUBIN

### Specimen UA-1

#### Participant Results

<u>Method</u>	<u>Negative</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	43	35	30	1
Arkray Aution Sticks	3	5	1	-
Arkray PocketChem UA	-	1	1	-
Bayer Clinitek 10 / 100	1	-	-	-
Bayer Clinitek 50	-	-	1	1
Bayer Clinitek 500	5	1	15	-
Bayer Clinitek Atlas	-	-	3	-
Bayer Clinitek Status	-	-	1	-
Bayer Reagent Strips	5	-	4	-
BioScan Reagent Strips	1	-	-	-
Quidel QuickVue UrinChek	-	1	-	-
Roche (BMC) Chemstrips	17	6	-	-
Roche (BMC) Criterion Analyzer	2	-	-	-
Roche (BMC) Mini UA	2	2	-	-
Roche Miditron	1	1	-	-
Roche Urisys	-	5	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-
UriScan Reagent Strips	1	9	3	-

**URINALYSIS DIPSTICK–UROBILINOGEN**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>0.2/Normal mg/dL</u>	<u>1.0 mg/dL</u>	<u>2.0 mg/dL</u>	<u>4.0 mg/dL</u>	<u>&gt;8.0 mg/dL</u>
ALL METHODS	105	3	1	-	-
Arkray Aution Sticks	9	-	-	-	-
Arkray PocketChem UA	2	-	-	-	-
Bayer Clinitek 10 / 100	1	-	-	-	-
Bayer Clinitek 50	2	-	-	-	-
Bayer Clinitek 500	21	-	-	-	-
Bayer Clinitek Atlas	3	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	9	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	23	1	-	-	-
Roche (BMC) Criterion Analyzer	2	-	-	-	-
Roche (BMC) Mini UA	4	-	-	-	-
Roche Mditron	2	-	-	-	-
Roche Urisys	3	1	1	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Reagent Strips	11	1	-	-	-

**URINALYSIS DIPSTICK–BLOOD/HEMOGLOBIN**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	100	1	7	2	1
Arkray Aution Sticks	9	-	-	-	-
Arkray PocketChem UA	2	-	-	-	-
Bayer Clinitek 10 / 100	1	-	-	-	-
Bayer Clinitek 50	2	-	-	-	-
Bayer Clinitek 500	21	-	-	-	-
Bayer Clinitek Atlas	3	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	9	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	18	1	4	-	1
Roche (BMC) Criterion Analyzer	2	-	-	-	-
Roche (BMC) Mini UA	4	-	-	-	-
Roche Mditron	2	-	-	-	-
Roche Urisys	2	-	3	-	-
Roche(BMC) SuperUA/ChemstripUA	4	-	-	-	-
UriScan Reagent Strips	13	-	-	-	-

**URINALYSIS DIPSTICK–LEUKOCYTE ESTERASE**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	1	-	-	9	99
Arkray Aution Sticks	-	-	-	1	8
Arkray PocketChem UA	-	-	-	1	1
Bayer Clinitek 10 / 100	-	-	-	-	1
Bayer Clinitek 50	-	-	-	-	2
Bayer Clinitek 500	1	-	-	-	19
Bayer Clinitek Atlas	-	-	-	-	3
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	-	-	-	5	4
BioScan Reagent Strips	-	-	-	1	-
Quidel QuickVue UrinChek	-	-	-	-	1
Roche (BMC) Chemstrips	-	-	-	-	24
Roche (BMC) Criterion Analyzer	-	-	-	-	2
Roche (BMC) Mini UA	-	-	-	-	4
Roche Miditron	-	-	-	-	2
Roche Urisys	-	-	-	-	5
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	4
UriScan Reagent Strips	-	-	-	-	13

**URINALYSIS DIPSTICK–NITRITE**

**Specimen UA-1**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	2	108
Arkray Aution Sticks	-	8
Arkray PocketChem UA	-	2
Bayer Clinitek 10 / 100	-	1
Bayer Clinitek 50	-	2
Bayer Clinitek 500	1	20
Bayer Clinitek Atlas	-	3
Bayer Clinitek Status	-	1
Bayer Reagent Strips	-	9
BioScan Reagent Strips	-	1
Quidel QuickVue UrinChek	-	1
Roche (BMC) Chemstrips	1	23
Roche (BMC) Criterion Analyzer	-	2
Roche (BMC) Mini UA	-	3
Roche Miditron	-	2
Roche Urisys	-	5
Roche(BMC) SuperUA/ChemstripUA	-	3
UriScan Reagent Strips	-	13

**URINALYSIS –MICROALBUMIN (dipstick only)****Specimen UA-1***Participant Results*

<u>Method</u>	<u>Negative</u>	<u>10 mg/L(Pos)</u>	<u>20/30 mg/L</u>	<u>50 mg/L (+)</u>	<u>80 mg/L</u>	<u>100 mg/L (++)</u>	<u>150 mg/L</u>
ALL METHODS	5	1	-	-	-	-	-
Bayer Clinitek Microalbumin	1	1	-	-	-	-	-
Roche (BMC) Micral - 1 minute	2	-	-	-	-	-	-

**URINALYSIS –URINE hCG****Specimen UA-1***Participant Results*

<u>Method</u>	<u>Sensitivity (mIU/mL)</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	-	11	2
Acon Laboratories	-	-	1
bioMerieux VIKIA hCG-D	-	6	-
Hybritech Icon II Serum/Urine	-	1	-

**ANTIMICROBIAL SUSCEPTIBILITY TESTING**

**Specimen SUS-1**

<u>Antimicrobial</u>	<u>-----Agar Diffusion-----</u> <u>Interpretative category data</u>				<u>-----MIC-----</u> <u>Interpretative category data</u>				<u>Acceptable (%)</u>
	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	
Amikacin	1	1	-	-	5	5	-	-	Not graded <sup>1</sup>
Amoxicillin/Clavulanate	1	1	-	-	3	2	-	1	Not graded <sup>1</sup>
Ampicillin	7	6	-	1	34	32	-	2	89.83%
Ampicillin/Sulbactam	3	3	-	-	5	2	-	3	Not graded <sup>1</sup>
Aztreonam	-	-	-	-	3	3	-	-	100%
Cefazolin	-	-	-	-	2	-	-	2	80%
Cefepime	-	-	-	-	3	2	-	1	Not graded <sup>1</sup>
Cefixime	1	1	-	-	-	-	-	-	100%
Cefotaxime	1	1	-	-	2	2	-	-	100%
Cefotetan	-	-	-	-	1	1	-	-	100%
Cefoxitin	1	-	-	1	-	-	-	-	100%
Ceftazidime	-	-	-	-	3	3	-	-	100%
Ceftriaxone	1	-	1	-	3	2	1	-	Not graded <sup>1</sup>
Cefuroxime	-	-	-	-	2	1	-	1	Not graded <sup>1</sup>
Cephalothin	2	1	1	-	2	1	-	1	Not graded <sup>1</sup>
Chloramphenicol	-	-	-	-	4	4	-	-	100%
Ciprofloxacin	7	6	1	-	30	30	-	-	94.44%
Clindamycin	1	-	-	1	2	1	-	1	Not graded <sup>1</sup>
Daptomycin	-	-	-	-	2	2	-	-	100%
Gentamicin	3	2	-	1	11	10	1	-	80%
Imipenem	1	1	-	-	5	5	-	-	91.67%
Levofloxacin	-	-	-	-	15	15	-	-	95.65%
Linezolid	-	-	-	-	14	14	-	-	100%
Meropenem	-	-	-	-	2	2	-	-	100%
Nalidixic Acid	1	-	-	1	-	-	-	-	Not graded <sup>1</sup>
Nitrofurantoin	7	7	-	-	30	29	1	-	96.23%
Norfloxacin	4	4	-	-	4	4	-	-	100%
Oxacillin	1	-	-	1	2	-	-	2	83.33%
Penicillin	3	3	-	-	29	28	-	1	93.48%
Piperacillin	-	-	-	-	1	1	-	-	100%
Piperacillin/Tazobactam	-	-	-	-	2	2	-	-	100%
Quinupristin/Dalfopristin	-	-	-	-	3	-	-	3	100%
Rifampin	1	-	1	-	9	9	-	-	85.71%
Teicoplanin	-	-	-	-	1	-	-	-	100%
Tetracycline	1	-	-	1	26	-	8	18	Not graded <sup>1</sup>
Ticarcillin/Clavulanate	-	-	-	-	2	1	1	-	Not graded <sup>1</sup>
Tobramycin	-	-	-	-	2	2	-	-	100%
Trimethoprim	3	3	-	-	-	-	-	-	100%
Trimethoprim/Sulfamethoxazole	2	2	-	-	5	5	-	-	90.91%
Vancomycin	7	5	2	-	29	29	-	-	96.23%

Organism present in specimen SUS-1: *Enterococcus faecalis*.

<sup>1</sup> This is an ungraded challenge due to less than 80% participant consensus.

## PARASITOLOGY (PA Specimens)

### Specimen PA-1

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	1	100%	Unacceptable

Parasite present in specimen PA-1: *Giardia lamblia*.

### Specimen PA-2

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	1	100%	Unacceptable

Parasite present in specimen PA-2: *Endolimax nana*.

### Specimen PA-3

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Hookworm	5	55.56%	Acceptable
Entamoeba coli	2	22.22%	
No parasite seen	1	11.11%	
Ascaris lumbricoides eggs	1	11.11%	

Parasites present in specimen PA-3: Hookworm, *Giardia lamblia* and *Trichuris trichiura* eggs.

### Specimen PA-4

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	5	71.43%	Acceptable
Ascaris lumbricoides eggs	1	14.29%	
Hookworm	1	14.29%	

Parasite present in specimen PA-4: No parasite seen.

### Specimen PA-5

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Plasmodium sp., NOS	3	37.50%	Acceptable
Other parasite seen but no ID	1	12.50%	Acceptable
Plasmodium vivax	4	50.00%	

Parasite present in specimen PA-5: *Plasmodium malariae*.

## PARASITOLOGY (FP Specimens)

### Specimen FP-1

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Giardia lamblia	78	93.98%	Acceptable
No parasite seen	2	2.41%	
Trichuris trichiura eggs	1	1.20%	
Blastocystis hominis	1	1.20%	
Chilomastix mesnili	1	1.20%	

Parasite present in specimen FP-1: *Giardia lamblia*.

### Specimen FP-2

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Entamoeba coli	77	45.56%	Acceptable
Endolimax nana	61	36.09%	
Entamoeba histolytica	26	15.38%	
Entamoeba hartmanni	1	0.59%	
Hookworm	1	0.59%	
Trypanosoma cruzi	1	0.59%	
Ascaris lumbricoides eggs	1	0.59%	
Blastocystis hominis	1	0.59%	

Parasite present in specimen FP-2: *Entamoeba coli*.

### Specimen FP-3

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Hookworm	66	60.55%	Acceptable
Parasite egg seen but no ID	4	3.67%	Acceptable
Entamoeba coli	11	10.09%	
Blastocystis hominis	10	9.17%	
Entamoeba histolytica	4	3.67%	
Ascaris lumbricoides eggs	4	3.67%	
Strongyloides stercoralis larvae	2	1.83%	
Trichostrongylus sp. eggs	2	1.83%	
Enterobius vermicularis eggs	2	1.83%	
Iodamoeba butschlii	1	0.92%	
Entamoeba hartmanni	1	0.92%	
Parasite larva seen but no ID	1	0.92%	
No parasite seen	1	0.92%	

Parasites present in specimen FP-3: Hookworm, *Giardia lamblia* and *Trichuris trichiura* eggs.

**PARASITOLOGY (FP Specimens)**

**Specimen FP-4**

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	66	78.57%	Acceptable
Blastocystis hominis	9	10.71%	
Endolimax nana	3	3.57%	
Entamoeba coli	3	3.57%	
Iodamoeba butschlii	1	1.19%	
Nonpath. protozoan present	1	1.19%	
Ascaris lumbricoides eggs	1	1.19%	

Parasite present in specimen FP-4: No parasite seen.

**Specimen FP-5**

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Trypanosoma cruzi	32	38.55%	Acceptable
Trypanosoma sp., NOS	31	37.35%	Acceptable
Other parasite seen but no ID	1	1.20%	Acceptable
Leishmania sp.	9	10.84%	
Trypanosoma gambiense	3	3.61%	
Iodamoeba butschlii	1	1.20%	
Isospora belli oocysts	1	1.20%	
Paragonimus westermani eggs	1	1.20%	
No parasite seen	1	1.20%	
Microfilaria-Loa loa	1	1.20%	
Plasmodium falciparum	1	1.20%	
Plasmodium vivax	1	1.20%	

Parasite present in specimen FP-5: *Trypanosoma cruzi*.

**Syphilis Serology—Qualitative: VDRL Slide**

<u>Method</u>	<u>Specimen SY-1</u>			<u>Specimen SY-2</u>			<u>Specimen SY-3</u>		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	9	-	-	6	3	-	1	-	9
BioBacter	1	-	-	-	1	-	-	-	2
Wiener Lab	7	-	-	6	1	-	1	-	6
<u>Method</u>	<u>Specimen SY-4</u>			<u>Specimen SY-5</u>					
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>			
ALL METHODS	6	2	1	-	-	10			
BioBacter	-	1	-	-	-	2			
Wiener Lab	6	1	-	-	-	7			

**Syphilis Serology—Quantitative: VDRL Slide Titer**

<u>Specimen/Method</u>	<u>0 dils</u>	<u>1 dil</u>	<u>2 dils</u>	<u>4 dils</u>	<u>8 dils</u>	<u>16 dils</u>	<u>32 dils</u>	<u>&gt;32 dils</u>
<b>Specimen SY-1</b>								
ALL METHODS	1	1	1	3	2	1	-	-
BioBacter	-	1	1	-	-	-	-	-
Wiener Lab	1	-	-	3	2	1	-	-
<b>Specimen SY-2</b>								
ALL METHODS	1	1	3	3	-	-	-	-
BioBacter	1	1	-	-	-	-	-	-
Wiener Lab	-	-	3	3	-	-	-	-
<b>Specimen SY-4</b>								
ALL METHODS	1	1	4	2	-	-	-	-
BioBacter	1	1	-	-	-	-	-	-
Wiener Lab	-	-	4	2	-	-	-	-

**Syphilis Serology—Qualitative: MHA-TP**

<u>Method</u>	<u>Specimen SY-1</u>		<u>Specimen SY-2</u>		<u>Specimen SY-3</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	6	-	6	-	-	5
Human	1	-	1	-	-	1
Serodia	3	-	3	-	-	2
<b>Specimen SY-4</b>						
ALL METHODS	6	-	-	5		
Human	1	-	-	1		
Serodia	3	-	-	2		

**Syphilis Serology—Qualitative: FTA-ABS (*Treponema pallidum* Antibodies)**

<u>Method</u>	<u>Specimen SY-1</u>		<u>Specimen SY-2</u>		<u>Specimen SY-3</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	8	-	8	-	3	5
Biokit	1	-	1	-	1	-
bioMerieux	3	-	3	-	1	2
Bio-Rad Evolis	1	-	1	-	1	-
SPINREACT	1	-	1	-	-	1
<b>Specimen SY-4</b>						
ALL METHODS	8	-	3	5		
Biokit	1	-	1	-		
bioMerieux	3	-	1	2		
Bio-Rad Evolis	1	-	1	-		
SPINREACT	1	-	-	1		

**Syphilis Serology—Qualitative: RPR**

<u>Method</u>	<b>Specimen SY-1</b>		<b>Specimen SY-2</b>		<b>Specimen SY-3</b>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	21	-	20	1	-	21
Abbott Syfacard-R	2	-	2	-	-	2
Becton Dickinson	3	-	3	-	-	3
bioMerieux	3	-	3	-	-	3
Immunostics Inc.	1	-	-	1	-	1
Omega Diagnostics	3	-	3	-	-	3
SPINREACT	5	-	5	-	-	5
Wiener Lab	1	-	1	-	-	1

  

<u>Method</u>	<b>Specimen SY-4</b>		<b>Specimen SY-5</b>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	21	-	2	19
Abbott Syfacard-R	2	-	-	2
Becton Dickinson	3	-	-	3
bioMerieux	3	-	1	2
Immunostics Inc.	1	-	-	1
Omega Diagnostics	3	-	-	3
SPINREACT	5	-	-	5
Wiener Lab	1	-	-	1

**Syphilis Serology—Quantitative: RPR (Titer)**

<u>Specimen/Method</u>	<u>1</u>	<u>2</u>	<u>4</u>	<u>8</u>	<u>16</u>	<u>32</u>	<u>64</u>	<u>&gt;64</u>
<b>Specimen SY-1</b>								
ALL METHODS	1	2	7	4	-	-	-	1
Abbott Syfacard-R	1	-	1	-	-	-	-	-
bioMerieux	-	1	1	1	-	-	-	-
Omega Diagnostics	-	-	-	2	-	-	-	1
SPINREACT	-	-	3	1	-	-	-	-
Wiener Lab	-	-	1	-	-	-	-	-
<b>Specimen SY-2</b>								
ALL METHODS	2	9	2	1	-	-	-	1
Abbott Syfacard-R	-	2	-	-	-	-	-	-
bioMerieux	1	1	-	1	-	-	-	1
Omega Diagnostics	-	1	1	-	-	-	-	-
SPINREACT	-	3	1	-	-	-	-	-
Wiener Lab	-	1	-	-	-	-	-	1
<b>Specimen SY-4</b>								
ALL METHODS	4	5	4	-	-	-	-	1
Abbott Syfacard-R	1	1	-	-	-	-	-	-
bioMerieux	1	1	-	-	-	-	-	-
Omega Diagnostics	-	-	2	-	-	-	-	1
SPINREACT	1	1	2	-	-	-	-	-
Wiener Lab	-	1	-	-	-	-	-	-

**Viral Markers – Anti-HBc**

<b><u>Method</u></b>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	3	37	34	6	35	5
Abbott Architect	-	3	3	-	3	-
Abbott Architect - IgG	-	1	1	-	1	-
Abbott AxSYM	-	2	2	-	2	-
Abbott AxSYM - IgM	-	2	-	2	-	2
Abbott AxSYM - Total	-	10	10	-	10	-
bioMerieux Vidas - IgM	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	1	1	-	1	-
Bio-Rad Evolis	-	2	2	-	2	-
DiaSorin	1	-	1	-	1	-
Other IgG Method	-	2	2	-	2	-
Other Total Method	1	2	3	-	3	-
Roche Elecsys - IgM	-	1	-	1	-	1
Roche Elecsys 1010/2010	1	3	4	-	4	-
Roche Modular Analytics	-	1	1	-	1	-
VITROS ECI	-	6	4	2	5	1
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHODS	1	39	35	5		
Abbott Architect	-	3	3	-		
Abbott Architect - IgG	-	1	1	-		
Abbott AxSYM	-	2	2	-		
Abbott AxSYM - IgM	-	2	-	2		
Abbott AxSYM - Total	-	10	10	-		
bioMerieux Vidas - IgM	-	1	-	1		
bioMerieux Vitek, Mini Vidas	-	1	1	-		
Bio-Rad Evolis	-	2	2	-		
DiaSorin	1	-	1	-		
Other IgG Method	-	2	2	-		
Other Total Method	-	3	3	-		
Roche Elecsys - IgM	-	1	-	1		
Roche Elecsys 1010/2010	-	4	4	-		
Roche Modular Analytics	-	1	1	-		
VITROS ECI	-	6	5	1		

**Viral Markers – Anti-HIV**

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	49	-	48	-	43
Abbott Architect	-	2	-	2	-	2
Abbott AxSYM	-	2	-	2	-	1
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	13	-	12	-	8
Bayer ADVIA Centaur	-	1	-	1	-	1
bioMerieux Vidas - IgM	-	2	-	2	-	2
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
Bio-Rad Evolis	-	2	-	2	-	2
Other IgG Method	-	2	-	2	-	2
Other Total Method	-	11	-	11	-	11
Roche Elecsys 1010/2010	-	7	-	7	-	7
Roche Modular Analytics	-	1	-	1	-	1
VITROS ECI	-	4	-	4	-	4
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHODS	-	49	-	45		
Abbott Architect	-	2	-	2		
Abbott AxSYM	-	2	-	2		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	13	-	9		
Bayer ADVIA Centaur	-	1	-	1		
bioMerieux Vidas - IgM	-	2	-	2		
bioMerieux Vitek, Mini Vidas	-	1	-	1		
Bio-Rad Evolis	-	2	-	2		
Other IgG Method	-	2	-	2		
Other Total Method	-	11	-	11		
Roche Elecsys 1010/2010	-	7	-	7		
Roche Modular Analytics	-	1	-	1		
VITROS ECI	-	4	-	4		

## Viral Markers – HAV

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	34	-	34	17	17
Abbott Architect - IgG	-	1	-	1	1	-
Abbott AxSYM	-	3	-	3	3	-
Abbott AxSYM - IgM	-	4	-	4	-	4
Abbott AxSYM - Total	-	4	-	4	4	-
Bayer ADVIA Centaur	-	1	-	1	1	-
bioMerieux Vidas - IgM	-	5	-	5	-	5
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
Other IgG Method	-	2	-	2	2	-
Other IgM method	-	2	-	2	-	2
Other Total Method	-	1	-	1	1	-
Roche Elecsys - IgM	-	4	-	4	-	4
Roche Elecsys 1010/2010	-	4	-	4	4	-
Roche Modular Analytics	-	1	-	1	1	-
VITROS ECI - IgM	-	1	-	1	-	1
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHODS	32	1	17	17		
Abbott Architect - IgG	1	-	1	-		
Abbott AxSYM	3	-	3	-		
Abbott AxSYM - IgM	4	-	-	4		
Abbott AxSYM - Total	4	-	4	-		
Bayer ADVIA Centaur	1	-	1	-		
bioMerieux Vidas - IgM	5	-	-	5		
bioMerieux Vitek, Mini Vidas	1	-	-	1		
Other IgG Method	2	-	2	-		
Other IgM method	2	-	-	2		
Other Total Method	-	1	1	-		
Roche Elecsys - IgM	3	-	-	4		
Roche Elecsys 1010/2010	4	-	4	-		
Roche Modular Analytics	1	-	1	-		
VITROS ECI - IgM	1	-	-	1		

Specimen VM-1: Total is non-reactive.

Specimen VM-2: Total is non-reactive.

Specimen VM-3: Total is reactive and IgM is non-reactive.

Specimen VM-4: Total and IgM are reactive.

Specimen VM-5: Total is reactive and IgM is non-reactive.

**Viral Markers – HBeAg**

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	2	15	2	15	2	15
Abbott AxSYM	-	1	-	1	-	1
Abbott AxSYM - Total	-	3	-	3	-	3
bioMerieux Vidas - IgM	-	1	1	-	1	-
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
DiaSorin	-	1	-	1	-	1
Other IgG Method	-	1	-	1	-	1
Other Total Method	-	2	-	2	-	2
Roche Elecsys 1010/2010	-	3	-	3	-	3
Roche Modular Analytics	-	1	-	1	-	1
VITROS ECI	2	1	1	2	1	2
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHODS	1	16	3	14		
Abbott AxSYM	-	1	-	1		
Abbott AxSYM - Total	-	3	-	3		
bioMerieux Vidas - IgM	-	1	1	-		
bioMerieux Vitek, Mini Vidas	-	1	-	1		
DiaSorin	-	1	-	1		
Other IgG Method	-	1	-	1		
Other Total Method	-	2	-	2		
Roche Elecsys 1010/2010	-	3	-	3		
Roche Modular Analytics	-	1	-	1		
VITROS ECI	1	2	2	1		

**Viral Markers – HBsAb**

<b><u>Method</u></b>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	1	35	2	33	4	30
Abbott Architect	-	1	-	1	-	1
Abbott AxSYM	-	5	-	5	-	5
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	5	-	5	-	5
Bayer ADVIA Centaur	-	2	-	2	-	2
bioMerieux Vidas - IgM	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
DiaSorin	-	1	-	1	-	1
Other IgG Method	1	-	-	1	1	-
Other Total Method	-	7	1	5	3	3
Roche Elecsys 1010/2010	-	7	-	7	-	7
Roche Modular Analytics	-	2	1	1	-	1
VITROS ECi	-	2	-	2	-	2
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHODS	1	35	3	31		
Abbott Architect	-	1	-	1		
Abbott AxSYM	-	5	-	5		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	5	-	5		
Bayer ADVIA Centaur	-	2	-	2		
bioMerieux Vidas - IgM	-	1	-	1		
bioMerieux Vitek, Mini Vidas	-	1	1	-		
DiaSorin	-	1	-	1		
Other IgG Method	-	1	-	1		
Other Total Method	1	6	2	4		
Roche Elecsys 1010/2010	-	7	-	7		
Roche Modular Analytics	-	2	-	1		
VITROS ECi	-	2	-	2		

**Viral Markers – Anti-HBsAg**

<u>Method</u>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	1	48	49	-	46	2
Abbott Architect	-	3	3	-	3	-
Abbott AxSYM	-	2	2	-	1	-
Abbott AxSYM - IgM	-	1	1	-	1	-
Abbott AxSYM - Total	-	11	11	-	10	1
Bayer ADVIA Centaur	-	1	1	-	1	-
bioMerieux Vidas - IgM	-	1	1	-	1	-
bioMerieux Vitek, Mini Vidas	-	1	1	-	1	-
Bio-Rad Evolis	-	2	2	-	2	-
DiaSorin	-	1	1	-	1	-
Other IgG Method	-	3	3	-	3	-
Other Total Method	-	8	8	-	7	1
Roche Elecsys - IgM	1	-	1	-	1	-
Roche Elecsys 1010/2010	-	6	6	-	6	-
Roche Modular Analytics	-	1	1	-	1	-
VITROS Eci	-	7	7	-	7	-
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHODS	1	48	49	-		
Abbott Architect	-	3	3	-		
Abbott AxSYM	-	2	2	-		
Abbott AxSYM - IgM	-	1	1	-		
Abbott AxSYM - Total	1	10	11	-		
Bayer ADVIA Centaur	-	1	1	-		
bioMerieux Vidas - IgM	-	1	1	-		
bioMerieux Vitek, Mini Vidas	-	1	1	-		
Bio-Rad Evolis	-	2	2	-		
DiaSorin	-	1	1	-		
Other IgG Method	-	3	3	-		
Other Total Method	-	8	8	-		
Roche Elecsys - IgM	-	1	1	-		
Roche Elecsys 1010/2010	-	6	6	-		
Roche Modular Analytics	-	1	1	-		
VITROS Eci	-	7	7	-		

**Viral Markers – HCV**

<b><u>Method</u></b>	<b>Specimen VM-1</b>		<b>Specimen VM-2</b>		<b>Specimen VM-3</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	-	44	1	43	44	-
Abbott Architect	-	1	-	1	1	-
Abbott Architect - IgG	-	1	-	1	1	-
Abbott AxSYM	-	1	-	1	1	-
Abbott AxSYM - IgM	-	1	-	1	1	-
Abbott AxSYM - Total	-	13	-	13	13	-
Abbott IMx	-	1	-	1	1	-
Bayer ADVIA Centaur	-	2	-	2	2	-
Bio-Rad Evolis	-	2	-	2	2	-
Other IgG Method	-	4	-	4	4	-
Other Total Method	-	11	1	10	11	-
VITROS Eci	-	7	-	7	7	-
	<b>Specimen VM-4</b>		<b>Specimen VM-5</b>			
ALL METHODS	-	44	44	-		
Abbott Architect	-	1	1	-		
Abbott Architect - IgG	-	1	1	-		
Abbott AxSYM	-	1	1	-		
Abbott AxSYM - IgM	-	1	1	-		
Abbott AxSYM - Total	-	13	13	-		
Abbott IMx	-	1	1	-		
Bayer ADVIA Centaur	-	2	2	-		
Bio-Rad Evolis	-	2	2	-		
Other IgG Method	-	4	4	-		
Other Total Method	-	11	11	-		
VITROS Eci	-	7	7	-		

## Blood Gases – pH

<u>Method</u>	Specimen BG-1					Specimen BG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	28	7.404	0.016	0.2	7.40	28	7.471	0.015	0.2	7.47
AVL OMNI	20	7.400	0.011	0.1	7.40	20	7.468	0.011	0.2	7.47
<u>Method</u>	Specimen BG-3					Specimen BG-4				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	28	7.131	0.019	0.3	7.14	28	7.137	0.019	0.3	7.14
AVL OMNI	20	7.132	0.018	0.3	7.13	20	7.134	0.014	0.2	7.14
<u>Method</u>	Specimen BG-5									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	28	7.337	0.016	0.2	7.34					
AVL OMNI	20	7.334	0.013	0.2	7.33					

## Blood Gases - pCO<sub>2</sub> (mmHg)

<u>Method</u>	Specimen BG-1					Specimen BG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	27	44.73	2.09	4.7	44.6	26	20.08	1.00	5.0	20.0
AVL OMNI	19	44.64	1.66	3.7	44.6	20	20.13	0.95	4.7	20.4
<u>Method</u>	Specimen BG-3					Specimen BG-4				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	28	61.94	2.91	4.7	61.4	28	58.59	2.68	4.6	58.0
AVL OMNI	20	61.88	2.89	4.7	61.4	20	58.50	2.54	4.3	58.0
<u>Method</u>	Specimen BG-5									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	28	38.04	1.56	4.1	38.0					
AVL OMNI	20	38.05	1.26	3.3	38.1					

## Blood Gases - pO<sub>2</sub> (mmHg)

<u>Method</u>	Specimen BG-1					Specimen BG-2				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	28	103.81	11.59	11.2	102.8	28	108.81	12.78	11.7	107.1
AVL OMNI	20	103.36	11.86	11.5	102.8	20	109.03	10.69	9.8	108.8
<u>Method</u>	Specimen BG-3					Specimen BG-4				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	28	115.38	13.41	11.6	117.0	28	113.92	10.62	9.3	115.4
AVL OMNI	20	116.00	13.14	11.3	117.1	20	115.19	10.15	8.8	116.4
<u>Method</u>	Specimen BG-5									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	28	76.08	9.99	13.1	78.2					
AVL OMNI	20	79.48	9.00	11.3	81.4					

**Blood Gases - Ionized Calcium (mmol/L)**

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-1</u>				<u>Specimen BG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	6	1.630	1.304	80.0	1.12	6	1.635	1.320	80.8	1.11

**Blood Gases - Chloride (mmol/L)**

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-1</u>				<u>Specimen BG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	96.1	4.5	4.7	95	7	99.7	6.2	6.2	98
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-3</u>				<u>Specimen BG-4</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	90.1	5.4	6.0	89	7	89.3	5.5	6.1	87
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-5</u>								
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	94.3	5.1	5.4	94					

**Blood Gases - Potassium (mmol/L)**

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-1</u>				<u>Specimen BG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	8	4.30	0.08	1.8	4.3	8	5.66	0.07	1.3	5.7
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-3</u>				<u>Specimen BG-4</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	8	3.29	0.16	5.0	3.3	8	3.29	0.16	5.0	3.3
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-5</u>								
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	8	4.88	0.07	1.5	4.9					

**Blood Gases - Sodium (mmol/L)**

<u>Method</u>	<u>Labs</u>	<u>Specimen BG-1</u>				<u>Specimen BG-2</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	8	130.6	2.1	1.6	131	8	149.8	1.9	1.3	149
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-3</u>				<u>Specimen BG-4</u>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	8	132.5	2.7	2.0	133	8	131.8	3.0	2.3	132
<u>Method</u>	<u>Labs</u>	<u>Specimen BG-5</u>								
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	8	135.5	2.1	1.5	135					

**Medical Laboratory Evaluation**

2011 Pennsylvania Avenue, NW, Suite 800

Washington, DC 20006-1813

800-338-2746 • 202-261-4500 • Fax: 202-835-0440

[www.acponline.org/mle](http://www.acponline.org/mle)